** Cancer drug developer Sellas Life Sciences Group's
shares rise 3.7% to $1.24
** Co says preclinical data showed its experimental drug, SLS009, demonstrated high efficacy in treating solid cancers with mutations in the ASXL1 gene
** Late last year, U.S. Food and Drug Administration granted SLS009 "orphan drug" status
** Orphan drug status is given to drugs that treat rare conditions, and are protected through a series of government incentives once in market
** Including session's gains, stock has risen 16.5% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。